It’s not surprising that there are mixed results because the study was very complex
Barcelona, Spain, (PRWEB) November 28, 2005
Following the initial release of the GAIT study abstract and recent presentations at the Annual Meeting of ACR (American College of Rheumatology) in San Diego, Dr Clegg, the lead researcher on the study added more positive information during the Chondroitin Symposium a Continuing Educational Program following this meeting.
The first relevant result reported that for the total patient population who participated in the study, the response to the combination of chondroitin and glucosamine was significantly higher than placebo using the OMERACT/OARSI (Osteoarthritis Research Society International) criteria. Placebo was 56% and Chondroitin (CS) + Glucosamine (GLU) was 65.6%. See attached document for details.
OMERACT is the most recent response criteria internationally validated by the OARSI for measuring the symptomatic efficacy of a substance in treating osteoarthritis.
This response varies significantly from the WOMAC (pain measurement) data that was originally presented by Dr. Clegg, in which a non-statistical effect for the overall population was shown for the chondroitin/glucosamine combination. “It’s not surprising that there are mixed results because the study was very complex,” comments Nicholas DiNubile MD and orthopaedic surgeon, “However, when all the data is finally available for review, the results will bear out what we experience in clinical practice, that chondroitin and glucosamine are highly effective and risk-free, in not only treating osteoarthritis but preventing and reversing the effects of the disease.” Dr. DiNubile has over 25 years experience in treating osteoarthritis. Chosen as one of the “Best Doctors in America”, DeNubile has been the recipient of the prestigious Healthy American Fitness Leaders award and also served as special advisor and medical consultant to The President’s Council on Physical Fitness and Sports under the first Bush Administration.
Significantly more data has yet to be released from this multi-armed GAIT study, and as further results are forthcoming the efficacy of chondroitin and glucosamine for the treatment of osteoarthritis will be confirmed.
The information contained in this release was extracted from the Chondroitin Symposium following the ACR scientific meeting. It was sponsored through an educational grant by Bioiberica SA. Bioiberica is the leading manufacturer of pharmaceutical-grade chondroitin sulfate and was selected by the NIH as the exclusive supplier of chondroitin sulfate for the GAIT study.
For more information, or to arrange an interview with a company spokesperson or a member of the medical advisory panel, please contact Leesa Raab at ADinfinitum, 212 693 2150 Ext. 309.
# # #